Enjoy complimentary customisation on priority with our Enterprise License!
Colorectal cancer is a type of cancer that affects colon or rectum. The risk factors identified for this cancer include age, family history, unhealthy lifestyle, genetic disorders, and inflammatory bowel disease. Different types of therapy such as chemotherapy, surgical, biologic, and radiation therapy are being developed and administered to the colorectal patients to alleviate this disease.
Technavio’s analysts expect the colorectal cancer therapeutics market in the APAC region to grow at a moderate rate, posting a CAGR of more than 6% during the forecast period.
The presence of high unmet medical need is one of the major drivers propelling the growth of the market. Colorectal cancers cannot be cured completely by the currently available therapies and if it has not metastasized, surgery would be the only treatment option. As a result, a drug manufacturer has immense opportunities to exploit and seek a favorable position in the market by developing appropriate drugs and mitigate this issue.
The small molecules segment includes chemical entities characterized by low molecular weight and a less complex structure as compared to biologics. They are easy to manufacture through chemical synthesis, more stable than biologics, and mostly non-immunogenic.
First-line chemotherapy therapy is the treatment regimen or regimens that are generally accepted by the medical establishment for primary treatment and stage of cancer. First-line therapy is also called as a standard therapy.
The colorectal cancer therapeutics market in the APAC region is witnessing moderate growth because of a rise in the prevalence of colorectal cancer and unmet medical needs. Therefore, companies that manufacture and market drugs that can treat colorectal cancer effectively and cure, besides exhibiting a high safety and efficacy profile, are expected to gain a competitive edge over other companies in this market.
Key vendors in this market are -
Other prominent vendors included in this report are Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, and Yakult Honsha.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Product profiles
PART 04: Market research methodology
PART 05: Introduction
PART 06: Disease overview
PART 07: Pipeline portfolio
PART 08: Market landscape
PART 09: Market segmentation by based on the type of molecules
PART 10: Market segmentation by route of administration
PART 11: Market segmentation by lines of chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Key vendor analysis
PART 19: Appendix
PART 20: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.